Innovative therapeutics

Investors

IR Snapshot

NASDAQBMRN
Beta1.28
Shares Outstanding179.6M
Average Volume (10 days)1.4M
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($0.25)
Sales (TTM)$8.75
Book Value (MRQ)$17.12
Cash Flow (TTM)$0.23
Cash (MRQ)$720,792,000.00

Analyst Views

Current Mean RecommendationStrong Buy
Strong Buy15
 
Buy1
 
Hold4
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Jean-Jacques Bienaime
Director, Chief Executive Officer
(5,000)
Sell
Oct 25, 2019
V. Bryan Lawlis
(3,750)
Sell
Sep 17, 2019
Elizabeth McKee Anderson
4,490
Acquire
Jul 9, 2019
V. Bryan Lawlis
(3,750)
Sell
Jun 17, 2019
G. Eric Davis
SVP, General Counsel
300
Dispose
Jun 5, 2019

Recent SEC Filings

Amended Quarterly Financials
Nov 4, 2019
Insider Buy/Sell
Oct 30, 2019
Quarterly Financials
Oct 29, 2019
Company Events
Oct 23, 2019
S-8
Oct 16, 2019

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information